EP0777476A4 - Procedes enrayant le cancer de l'uterus - Google Patents

Procedes enrayant le cancer de l'uterus

Info

Publication number
EP0777476A4
EP0777476A4 EP95930243A EP95930243A EP0777476A4 EP 0777476 A4 EP0777476 A4 EP 0777476A4 EP 95930243 A EP95930243 A EP 95930243A EP 95930243 A EP95930243 A EP 95930243A EP 0777476 A4 EP0777476 A4 EP 0777476A4
Authority
EP
European Patent Office
Prior art keywords
methods
endometrial cancer
inhibiting endometrial
inhibiting
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95930243A
Other languages
German (de)
English (en)
Other versions
EP0777476A1 (fr
Inventor
Susan Margaret Boss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0777476A1 publication Critical patent/EP0777476A1/fr
Publication of EP0777476A4 publication Critical patent/EP0777476A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP95930243A 1994-08-22 1995-08-21 Procedes enrayant le cancer de l'uterus Withdrawn EP0777476A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US293853 1981-08-18
US29385394A 1994-08-22 1994-08-22
PCT/US1995/010651 WO1996005833A1 (fr) 1994-08-22 1995-08-21 Procedes enrayant le cancer de l'uterus

Publications (2)

Publication Number Publication Date
EP0777476A1 EP0777476A1 (fr) 1997-06-11
EP0777476A4 true EP0777476A4 (fr) 1999-06-23

Family

ID=23130867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95930243A Withdrawn EP0777476A4 (fr) 1994-08-22 1995-08-21 Procedes enrayant le cancer de l'uterus

Country Status (17)

Country Link
EP (1) EP0777476A4 (fr)
JP (1) JPH10504824A (fr)
KR (1) KR970705387A (fr)
AU (1) AU688112B2 (fr)
CA (1) CA2198119A1 (fr)
CZ (1) CZ51897A3 (fr)
FI (1) FI970717A0 (fr)
HU (1) HUT76890A (fr)
IL (1) IL115022A (fr)
MX (1) MX9701327A (fr)
MY (1) MY113757A (fr)
NO (1) NO970783D0 (fr)
NZ (1) NZ292017A (fr)
RU (1) RU2161964C2 (fr)
TW (1) TW404834B (fr)
WO (1) WO1996005833A1 (fr)
ZA (1) ZA956994B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN115825414B (zh) * 2023-01-09 2023-04-25 中国医学科学院北京协和医院 血液或尿液代谢标志物及其在子宫内膜癌早筛中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0617030A1 (fr) * 1993-03-19 1994-09-28 Eli Lilly And Company Dérivés de sulphonate et carbamate de aroyl-3-benzo(bêta)thiophènes
WO1994023068A1 (fr) * 1993-04-07 1994-10-13 Ligand Pharmaceuticals, Incorporated Procede de triage concernant des agonistes de recepteurs
EP0652004A1 (fr) * 1993-10-15 1995-05-10 Eli Lilly And Company Méthode pour le traitement de néoplasmes résistants
WO1996005832A1 (fr) * 1994-08-22 1996-02-29 Eli Lilly And Company Procedes enrayant l'hyperplasie endometriale primaire
WO1996009050A1 (fr) * 1994-09-22 1996-03-28 Eli Lilly And Company Procedes d'inhibition des mitoses endometriales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0617030A1 (fr) * 1993-03-19 1994-09-28 Eli Lilly And Company Dérivés de sulphonate et carbamate de aroyl-3-benzo(bêta)thiophènes
WO1994023068A1 (fr) * 1993-04-07 1994-10-13 Ligand Pharmaceuticals, Incorporated Procede de triage concernant des agonistes de recepteurs
EP0652004A1 (fr) * 1993-10-15 1995-05-10 Eli Lilly And Company Méthode pour le traitement de néoplasmes résistants
WO1996005832A1 (fr) * 1994-08-22 1996-02-29 Eli Lilly And Company Procedes enrayant l'hyperplasie endometriale primaire
WO1996009050A1 (fr) * 1994-09-22 1996-03-28 Eli Lilly And Company Procedes d'inhibition des mitoses endometriales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOTTARDIS M M ET AL: "EFFECT OFSTEORIDAL AND NONSTEORIDAL ANTIESTROGENS ON THE GROWTH OF A TAMOXIFEN-STIMULATED HUMAN ENDOMETRIAL CARCINOMA (ENCA101) IN ATHYMIC MICE", CANCER RESEARCH, vol. 50, no. 11, pages 3189 - 3192, XP002041037 *
JORDAN V C: ""STUDIES ON THE ESTROGEN RECEPTOR IN BREAST CANCER" - 20 YEARS AS A TARGET FOR THE TREATMENT AND PREVENTION OF CANCER", BREAST CANCER RESEARCH AND TREATMENT, vol. 36, no. 3, 1995, pages 267 - 285, XP000654844 *
See also references of WO9605833A1 *

Also Published As

Publication number Publication date
TW404834B (en) 2000-09-11
IL115022A0 (en) 1998-06-15
MY113757A (en) 2002-05-31
KR970705387A (ko) 1997-10-09
IL115022A (en) 2000-07-31
AU688112B2 (en) 1998-03-05
WO1996005833A1 (fr) 1996-02-29
AU3370095A (en) 1996-03-14
JPH10504824A (ja) 1998-05-12
CZ51897A3 (en) 1997-06-11
NO970783L (no) 1997-02-20
EP0777476A1 (fr) 1997-06-11
CA2198119A1 (fr) 1996-02-29
NZ292017A (en) 2000-07-28
FI970717A (fi) 1997-02-20
MX9701327A (es) 1997-05-31
ZA956994B (en) 1997-02-21
NO970783D0 (no) 1997-02-20
RU2161964C2 (ru) 2001-01-20
HUT76890A (en) 1997-12-29
FI970717A0 (fi) 1997-02-20

Similar Documents

Publication Publication Date Title
ZA957483B (en) Compounds and methods for the treatment of cancer
PL311736A1 (en) Derivatives of 1h-imidazoles
PL329875A1 (en) Derivatives of carbolin
PL329195A1 (en) Derivatives of 6-phenylpyridol-2-amine
GB9719643D0 (en) Hydrate inhibition
GB2318734B (en) Methods of preventing breast cancer
PL312692A1 (en) New derivatives of dialkoxy-pyridinol-benzimidazole
GB9509572D0 (en) Cancer therapy
IL115022A0 (en) Methods of inhibiting endometrial cancer
ZA957949B (en) Methods of inhibiting endometrial mitroses
PL317236A1 (en) Derivatives of naphtoquinone
IL117277A0 (en) Methods of inhibiting ovarian cancer
GB9624800D0 (en) Methods of preventing breast cancer
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
GB9408533D0 (en) Assessment of distance
AU731388C (en) Methods of preventing breast cancer
GB9603150D0 (en) Methods of inhibiting colon tumors
ZA97621B (en) Methods of inhibiting colon tumors
IL125521A0 (en) Methods of inhibiting colon tumors
GB9408200D0 (en) Location of underground objects
TW358610U (en) Improvement of inter-com
GB9415903D0 (en) Hydrate inhibition
HU9400901D0 (en) Coctail of palwoelgy
GB9504415D0 (en) Novel treatments for cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 970218;LV PAYMENT 970218;SI PAYMENT 970218

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 31/445 A

A4 Supplementary search report drawn up and despatched

Effective date: 19990510

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20001115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040301